← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. PFE
  3. P/E History
OverviewAnalysisPriceRevenueEarningsP/ERatiosDividendTargets

PFE logoPfizer Inc. (PFE) P/E Ratio History

Historical price-to-earnings valuation from 1990 to 2026

Current P/E
19.4
Fair Value
5Y Avg P/E
19.3
+1% vs avg
PE Percentile
80%
High
PEG Ratio
N/A
N/A
TTM EPS$1.31
Price$26.44
5Y PE Range8.0 - 81.1
Earnings Yield5.14%

Loading P/E history...

PFE Valuation Context

How does the current P/E compare to historical and market benchmarks?

vs. 5Y Average
19.4vs19.3
+1%
In Line with History
vs. Healthcare
19.4vs22.2
-12%
Below Sector
vs. S&P 500
19.4vs25.1
-23%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on -4% EPS growth (1Y)
Export Data

P/E Ratio Analysis

As of May 6, 2026, Pfizer Inc. (PFE) trades at a price-to-earnings ratio of 19.4x, with a stock price of $26.44 and trailing twelve-month earnings per share of $1.31.

The current P/E is roughly in line with its 5-year average of 19.3x. Over the past five years, PFE's P/E has ranged from a low of 8.0x to a high of 81.1x, placing the current valuation at the 80th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.2x, PFE is roughly in line with its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 171.0x.

Relative to the broader market, PFE trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PFE DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

PFE P/E vs Peers

P/E ratio compared to closely matched public peers

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
JNJ logoJNJJohnson & Johnson
$544B39.0--58%
MRK logoMRKMerck & Co., Inc.
$279B15.5Lowest0.73Best+8%
ABBV logoABBVAbbVie Inc.
$365B87.0--1%
LLY logoLLYEli Lilly and Company
$934B43.11.49+96%
BMY logoBMYBristol-Myers Squibb Company
$116B16.5-+178%
AZN logoAZNAstraZeneca PLC
$281B27.71.27+191%Best
NVS logoNVSNovartis AG
$278B20.21.32+22%
AMGN logoAMGNAmgen Inc.
$178B23.27.87+88%
GILD logoGILDGilead Sciences, Inc.
$166B351.3--92%
BIIB logoBIIBBiogen Inc.
$28B21.4--21%

Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.

PFE Historical P/E Data (1990–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterDatePriceTTM EPSP/E Ratiovs Avg
FY2026 Q1Sun Mar 29 2026 00:00:00 GM$27.03$1.3120.6x-18%
FY2025 Q4Wed Dec 31 2025 00:00:00 GM$24.90$1.3618.3x-27%
FY2025 Q3Sun Sep 28 2025 00:00:00 GM$23.76$1.7213.8x-45%
FY2025 Q2Sun Jun 29 2025 00:00:00 GM$24.19$1.8912.8x-49%
FY2025 Q1Sun Mar 30 2025 00:00:00 GM$25.21$1.3818.3x-27%
FY2024 Q4$26.53$1.4118.8x-25%
FY2024 Q3Sun Sep 29 2024 00:00:00 GM$29.09$0.7439.3x+57%
FY2023 Q4Sun Dec 31 2023 00:00:00 GM$28.79$0.3581.1x+223%
FY2023 Q3Sun Oct 01 2023 00:00:00 GM$33.17$1.8218.2x-27%
FY2023 Q2Sun Jul 02 2023 00:00:00 GM$36.68$3.759.8x-61%
FY2023 Q1Sun Apr 02 2023 00:00:00 GM$40.80$5.078.0x-68%
FY2022 Q4Sat Dec 31 2022 00:00:00 GM$51.24$5.479.4x-63%

Average P/E for displayed period: 25.1x

Full PFE Stock Analysis

Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.

View Analysis

See PFE's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is PFE Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare PFE vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

PFE — Frequently Asked Questions

Quick answers to the most common questions about buying PFE stock.

Is PFE stock overvalued or undervalued?

PFE trades at 19.4x P/E, near its 5-year average of 19.3x. The 80th percentile ranking places valuation within normal historical bounds.

How does PFE's valuation compare to peers?

Pfizer Inc. P/E of 19.4x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.

What is PFE's PEG ratio?

PFE PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1990-2026.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

PFE P/E Ratio History (1990–2026)

P/E ratio calculated as closing price divided by trailing 12-month diluted EPS at each quarter end.